Blackstone Funds Pfizer's Obesity Drug Development

Blackstone Life Sciences will invest up to $1.5 billion to help Pfizer develop berobenatide, an investigational GLP-1 drug for chronic weight management.

Updated on Nov. 11, 2026 in Weight Loss

Blackstone Funds Pfizer's Obesity Drug Development

Live Poll

Would you take a new prescription weight-loss drug if your doctor recommended it?

Blackstone Life Sciences agreed to pay up to $1.5 billion to help Pfizer develop berobenatide, a GLP-1 receptor drug studied for chronic weight management and obesity-related conditions. Blackstone has not acquired any rights or ownership to the drug, and Pfizer retains full control over its operations and decisions.

Why it matters

Pfizer does not currently have a GLP-1 medication approved for weight loss on the market, so the funding supports a potential entry into a fast-growing obesity drug category. Outside investment of this kind lets Pfizer share development costs while keeping control of the program.

The agreement caps Blackstone's funding at $1.5 billion, with payments to Blackstone tied to regulatory and sales milestones that have not yet occurred. Pfizer plans 20 or more obesity trials in 2026, including 10 continuing and planned Phase 3 trials for berobenatide, but the outcome of those studies is unknown.

The players

Pfizer

Pfizer is a major U.S. pharmaceutical company that develops treatments across many therapeutic areas, including obesity and metabolic disease.

Blackstone Life Sciences

Blackstone Life Sciences is the life sciences investment arm of the global asset manager Blackstone, which provides capital to drug development programs.

The details

Blackstone's funding covers development costs for berobenatide, and the company may receive milestone-based payments over a multi-year period. Those payments depend on Pfizer obtaining U.S. regulatory approval and achieving commercial sales milestones.

Timeline

  1. Companies announced the Blackstone-Pfizer funding deal on Wednesday, November 11, 2026.

  2. Pfizer plans to advance 20 or more obesity and related-condition trials during 2026.

  3. Milestone payments to Blackstone are payable over a multi-year period after approval and sales targets are met.

Market Landscape

The deal positions Pfizer to compete in a GLP-1 obesity drug market already shaped by established weight-loss therapies from rival drugmakers. Pfizer's lack of an approved GLP-1 weight-loss medication means berobenatide would enter the market as a late challenger to the GLP-1 drugs already available.

Berobenatide is still investigational and is not yet available to patients, so no change to treatment options is possible until regulatory approval is granted. If approved in the United States, it would add a new GLP-1 option for chronic weight management, and patients should discuss any new medication with their doctor.

The takeaway

Outside financing can accelerate expensive drug development, but the payoff depends on regulatory approval and commercial success that remain uncertain. Readers should watch for trial results and approval decisions before drawing conclusions about berobenatide's role in obesity care.

Further reading

For more on the treatments driving this market, explore Weight Loss coverage on Wisevoter.

Live Poll

Would you take a new prescription weight-loss drug if your doctor recommended it?